Literature DB >> 12767996

Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) contains hypoxia response elements: relevance to lytic induction by hypoxia.

Muzammel Haque1, David A Davis, Victoria Wang, Isabelle Widmer, Robert Yarchoan.   

Abstract

Kaposi's sarcoma (KS)-associated herpesvirus (KSHV), also known as human herpesvirus 8, is an etiologic agent of KS, primary effusion lymphoma (PEL), and multicentric Castleman's disease. We recently demonstrated that hypoxia can induce lytic replication of KSHV in PEL cell lines. Hypoxia induces the accumulation of hypoxia-inducible factors (HIF), and we hypothesized that the KSHV genome may respond to hypoxia through functional hypoxia response elements (HREs). Here, we demonstrate the presence of at least two promoters within the KSHV genome that are activated by hypoxia or hypoxia mimics. One is in the promoter region of the gene for Rta, the main lytic switch gene, and the other is within the promoter region of ORF34, a lytic gene of unknown function. The ORF34 promoter contains three putative consensus HREs oriented in the direction of the gene. Dissection and site-directed mutagenesis studies confirmed that one of the HREs of the ORF34 promoter is functional. Under conditions of hypoxia, the ORF34 promoter was strongly upregulated by HIF-1 alpha and HIF-2 alpha. By contrast, the promoter of the gene for Rta appeared to be preferentially upregulated by HIF-2 alpha. Reverse transcription-PCR analysis revealed that specific messages for ORF34 and ORF50 are upregulated in BCBL-1 cells exposed to hypoxia. An HIF-1 binding and competition assay demonstrated that the HRE sequence from the ORF34 promoter can compete for HIF-1 alpha binding to an erythropoietin HRE oligonucleotide while a mutant sequence cannot. Thus, we demonstrated that a viral gene can be activated by hypoxia through activation of a functional viral HRE. To our knowledge, this is the first example of a functional HRE in a viral promoter.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12767996      PMCID: PMC156153          DOI: 10.1128/jvi.77.12.6761-6768.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes.

Authors:  S Salceda; J Caro
Journal:  J Biol Chem       Date:  1997-09-05       Impact factor: 5.157

2.  Identification of a variant B-specific neutralizing epitope on glycoprotein H of human herpesvirus-6.

Authors:  K Takeda; M Haque; T Sunagawa; T Okuno; Y Isegawa; K Yamanishi
Journal:  J Gen Virol       Date:  1997-09       Impact factor: 3.891

3.  Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8).

Authors:  J J Russo; R A Bohenzky; M C Chien; J Chen; M Yan; D Maddalena; J P Parry; D Peruzzi; I S Edelman; Y Chang; P S Moore
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

4.  Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells.

Authors:  G Miller; L Heston; E Grogan; L Gradoville; M Rigsby; R Sun; D Shedd; V M Kushnaryov; S Grossberg; Y Chang
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

5.  Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells.

Authors:  H Tian; S L McKnight; D W Russell
Journal:  Genes Dev       Date:  1997-01-01       Impact factor: 11.361

6.  Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1.

Authors:  B H Jiang; E Rue; G L Wang; R Roe; G L Semenza
Journal:  J Biol Chem       Date:  1996-07-26       Impact factor: 5.157

7.  A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development.

Authors:  M Ema; S Taya; N Yokotani; K Sogawa; Y Matsuda; Y Fujii-Kuriyama
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

8.  Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus.

Authors:  L Arvanitakis; E A Mesri; R G Nador; J W Said; A S Asch; D M Knowles; E Cesarman
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

9.  Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae.

Authors:  P S Moore; S J Gao; G Dominguez; E Cesarman; O Lungu; D M Knowles; R Garber; P E Pellett; D J McGeoch; Y Chang
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

10.  Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1.

Authors:  G L Semenza; B H Jiang; S W Leung; R Passantino; J P Concordet; P Maire; A Giallongo
Journal:  J Biol Chem       Date:  1996-12-20       Impact factor: 5.157

View more
  57 in total

1.  An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease.

Authors:  Thomas S Uldrick; Victoria Wang; Deirdre O'Mahony; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Seth M Steinberg; Stefania Pittaluga; Irina Maric; Denise Whitby; Giovanna Tosato; Richard F Little; Robert Yarchoan
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

2.  Hypoxia induces the gene expression and extracellular transmission of persistent lymphocytic choriomeningitis virus.

Authors:  Jana Tomaskova; Ingrid Oveckova; Martina Labudova; Lubomira Lukacikova; Katarina Laposova; Juraj Kopacek; Silvia Pastorekova; Jaromir Pastorek
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

3.  Kaposi's sarcoma-associated herpesvirus reactivation is regulated by interaction of latency-associated nuclear antigen with recombination signal sequence-binding protein Jkappa, the major downstream effector of the Notch signaling pathway.

Authors:  Ke Lan; Daniel A Kuppers; Erle S Robertson
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  Genetic organization and hypoxic activation of the Kaposi's sarcoma-associated herpesvirus ORF34-37 gene cluster.

Authors:  Muzammel Haque; Victoria Wang; David A Davis; Zhi-Ming Zheng; Robert Yarchoan
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  Kaposi's sarcoma-associated herpesvirus latent protein LANA interacts with HIF-1 alpha to upregulate RTA expression during hypoxia: Latency control under low oxygen conditions.

Authors:  Qiliang Cai; Ke Lan; Subhash C Verma; Huaxin Si; Doug Lin; Erle S Robertson
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

Review 6.  Epigenetic regulation of Kaposi's sarcoma-associated herpesvirus replication.

Authors:  Shara N Pantry; Peter G Medveczky
Journal:  Semin Cancer Biol       Date:  2009-02-21       Impact factor: 15.707

7.  Hypoxia enhances the replication of oncolytic herpes simplex virus.

Authors:  Manish K Aghi; Ta-Chiang Liu; Samuel Rabkin; Robert L Martuza
Journal:  Mol Ther       Date:  2008-10-28       Impact factor: 11.454

8.  The Kaposi's sarcoma-associated herpesvirus ORF34 protein binds to HIF-1α and causes its degradation via the proteasome pathway.

Authors:  Muzammel Haque; Konstantin G Kousoulas
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

9.  Role of protein kinase C delta in reactivation of Kaposi's sarcoma-associated herpesvirus.

Authors:  Einat Deutsch; Adina Cohen; Gila Kazimirsky; Sara Dovrat; Hadara Rubinfeld; Chaya Brodie; Ronit Sarid
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Viral Interleukin-6 by X-Box Binding Protein 1.

Authors:  Duosha Hu; Victoria Wang; Min Yang; Shahed Abdullah; David A Davis; Thomas S Uldrick; Mark N Polizzotto; Ravindra P Veeranna; Stefania Pittaluga; Giovanna Tosato; Robert Yarchoan
Journal:  J Virol       Date:  2015-10-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.